Karyopharm Therapeutics (KPTI) Agreement Removes Finance Overhang - Baird

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. AXP
9. TMUS
10. SPY

Go back to Karyopharm Therapeutics (KPTI) Agreement Removes Finance Overhang - Baird

Karyopharm Therapeutics (KPTI) Enters Royalty Agreement with Healthcare Royalty Partners for up to $150 Million

September 16, 2019 7:03 AM EDT

aryopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced its entry into a royalty agreement with HealthCare Royalty Partners (HCR) for up to $150 million to support the ongoing development and commercialization of XPOVIOTM (selinexor), the Companys first-in-class, oral SINE compound, which is currently marketed in the U.S. for the treatment of patients with heavily pretreated multiple myeloma. Selinexor is also in late-stage clinical development for the treatment of patients with relapsed or refractory multiple myeloma who have had one to three prior lines of therapy and for the... More